Business Wire

CO-SPATIAL-CORP

30.4.2024 09:01:33 CEST | Business Wire | Press release

Share
Spatial Announces Release 2024 1.0.1

Spatial Corp, the leading software development toolkit provider for design, manufacturing, and engineering solutions and Dassault Systèmes subsidiary, announces the production release of 2024 1.0.1.

Data Prep Is Officially Released

Open New Horizons in Data Import

After launching the alpha version, Data Prep, Spatial’s newest add-on product for 3D InterOp, is officially released to all customers. Supported strategies include filtering small bodies from a model, removing small holes and fillets, and generating an assembly structure from a part with duplicate bodies.

Over the past three months, customer interest confirms the market need for tools to simplify and optimize data during import. Spatial plans to invest further in Data Prep strategies. Functionality releasing soon includes:

  • Capabilities to reduce data to manage while preserving relevant features - to shorten model preparation times for multi-physics and process simulation workflows.
  • Ability to convert polyline data to continuous curves during file restore - to decrease memory consumption and allow for successful import.
  • Option to avoid model shrinkage due to Data Prep strategies like feature removal - to ensure accuracy of collision detection analyses.

Users interested in defining future strategies for Data Prep should contact their account manager.

3D InterOp Extends Support for BIM and Manufacturing

New Support for Navisworks and Writing DXF/DWG Drawing Sheets

The latest release allows BIM customers to read Navisworks files and write drawing sheets in a DXF/DWG format. Additionally, 3D InterOp offers expanded support for the Linux platform in Parasolid-based 3D InterOp.

Point and Table Patterns from Creo Files

Manufacturing relies on hole pattern metadata for automated machining processes such as drilling, milling, cutting, or punching. The latest release of 3D InterOp supports Point and Table type hole patterns in Creo Reader.

Enabling Support of More Formats through External Partners

Extensible 3D InterOp enables partners to create readers and writers for unsupported file formats. These external implementations integrate with existing formats to seamlessly exchange BREP and Visualization data. Customers wishing to develop custom readers and writers can reach out to their account manager for assistance.

Package Size Optimization

For customers not needing support for all bundled formats, ACIS-based 3D InterOp offers guidance on configuring a minimal library set for popular CAD and exchange formats. This minimizes the libraries shipped with their application, saving end-user disk space. For example, supporting only IGES + STEP formats reduces installed library size by 70%.

3D ACIS Modeler Improves Polyhedral Modeling

Polyhedral Sheet Thickening

Additive manufacturing or EDA workflows often start with input that is a 2D representation of a thin part to be processed. When printing or simulating the part, generating a realistic 3D model representing the object with its actual thickness is helpful. This release delivers an API to generate a thickened body from polyhedral sheets.

New Polyhedral Boolean Operations

ACIS now provides functionality to compute the intersection graph between two polyhedral bodies. It also allows combining disjointed polyhedral bodies into a single body, increasing the efficiency of downstream operations.

CGM Provides More Manufacturing Automation and Simulation Tools

Enhancements to Feature Recognition and Removal

Users can now specify an industry context to customize the behavior of feature recognition. Setting the industry context tailors feature recognition to provide intuitive results for applications as diverse as Body-in-White, Micro-Mechanics, and Civil Engineering. This release also offers functionality to remove chamfers.

Improved Polyhedral Modeling for Additive Manufacturing

This release provides various robustness and performance enhancements targeting polyhedral healing and offset. For both types of operations, options are now available to tune the performance for specific configurations.

New Medial Axis Extraction Operator

Simulation engineers need tools to simplify the geometry of parts to reduce analysis computation time. This release features the beta version of the Neutral Fiber Operator, which reduces radially symmetric 3D bodies to a one-dimensional line.

CSM/CVM: Improvements to Cartesian Core Workflows

CVM generates Cartesian elements for interior meshing, resulting in accurate triangular surface meshes and predominantly hexahedral volume meshes. Users can now control the size of these elements, which were previously determined automatically based on surface mesh element size.

About Spatial Corp.

Spatial Corp, a Dassault Systèmes subsidiary, is the leading provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial’s 3D software development toolkits have been adopted by many of the world’s most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, Germany, Japan, China, and the United Kingdom. For more information, visit www.spatial.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430297301/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye